IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.
IDH wild type
Lower-grade glioma
Molecular glioblastoma
TERT promoter mutation
Journal
Brain tumor pathology
ISSN: 1861-387X
Titre abrégé: Brain Tumor Pathol
Pays: Japan
ID NLM: 9716507
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
06
03
2023
accepted:
09
05
2023
medline:
3
7
2023
pubmed:
22
5
2023
entrez:
22
5
2023
Statut:
ppublish
Résumé
The WHO 2021 classification defines IDH wild type (IDHw) histologically lower-grade glioma (hLGG) as molecular glioblastoma (mGBM) if TERT promoter mutation (pTERTm), EGFR amplification or chromosome seven gain and ten loss aberrations are indicated. We systematically reviewed articles of IDHw hLGGs studies (49 studies, N = 3748) and meta-analyzed mGBM prevalence and overall survival (OS) according to the PRISMA statement. mGBM rates in IDHw hLGG were significantly lower in Asian regions (43.7%, 95% confidence interval [CI: 35.8-52.0]) when compared to non-Asian regions (65.0%, [CI: 52.9-75.4]) (P = 0.005) and were significantly lower in fresh-frozen specimen when compared to formalin-fixed paraffin-embedded samples (P = 0.015). IDHw hLGGs without pTERTm rarely expressed other molecular markers in Asian studies when compared to non-Asian studies. Patients with mGBM had significantly longer OS times when compared to histological GBM (hGBM) (pooled hazard ratio (pHR) 0.824, [CI: 0.694-0.98], P = 0.03)). In patients with mGBM, histological grade was a significant prognostic factor (pHR 1.633, [CI: 1.09-2.447], P = 0.018), as was age (P = 0.001) and surgical extent (P = 0.018). Although bias risk across studies was moderate, mGBM with grade II histology showed better OS rates when compared to hGBM.
Identifiants
pubmed: 37212969
doi: 10.1007/s10014-023-00463-8
pii: 10.1007/s10014-023-00463-8
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Telomerase
EC 2.7.7.49
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-157Informations de copyright
© 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology.
Références
Adachi JI, Shirahata M, Suzuki T et al (2021) Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma. Brain Tumor Pathol 38:201–209
pubmed: 34128111
doi: 10.1007/s10014-021-00403-4
Aibaidula A, Chan AK, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327–1337
pubmed: 28575485
pmcid: 5596181
doi: 10.1093/neuonc/nox078
Akyerli CB, Yuksel S, Can O et al (2018) Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg 128:1102–1114
pubmed: 28621624
doi: 10.3171/2016.11.JNS16973
Aoki K, Nakamura H, Suzuki H et al (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol 20:66–77
pubmed: 29016839
doi: 10.1093/neuonc/nox132
Arita H, Ichimura K (2022) Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas. Brain Tumor Pathol 39:121–129
pubmed: 35098369
doi: 10.1007/s10014-021-00424-z
Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun 4:79. https://doi.org/10.1186/s40478-016-0351-2
doi: 10.1186/s40478-016-0351-2
pubmed: 27503138
pmcid: 4977715
Bale TA, Jordan JT, Rapalino O et al (2019) Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol 21:596–605
pubmed: 30496526
doi: 10.1093/neuonc/noy201
Bell EH, Zhang P, Shaw EG et al (2020) Comprehensive genomic analysis in NRG oncology/RTOG 9802: A Phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38:3407–3417
pubmed: 32706640
pmcid: 7527157
doi: 10.1200/JCO.19.02983
Berzero G, Di Stefano AL, Ronchi S et al (2021) IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol 23:955–966
pubmed: 33173941
doi: 10.1093/neuonc/noaa258
Bieńkowski M, Wöhrer A, Moser P et al (2018) Molecular diagnostic testing of diffuse gliomas in the real-life setting: a practical approach. Clin Neuropathol 37:166–177
pubmed: 29923492
pmcid: 6102559
doi: 10.5414/NP301110
Brat DJ Ed, Figarella-Branger D, et al. (2021) Gliomas, glioneuronal tumours, and neuronal tumours. In: Board Wcote (editor) Central nervous system tumours 5th edn. International Agency for Research on Cancer pp 15–187
Brito C, Azevedo A, Esteves S et al (2019) Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer 19:968. https://doi.org/10.1186/s12885-019-6177-0
doi: 10.1186/s12885-019-6177-0
pubmed: 31623593
pmcid: 6798410
Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498
doi: 10.1056/NEJMoa1402121
Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563
pubmed: 26824661
pmcid: 4754110
doi: 10.1016/j.cell.2015.12.028
Chan AK, Shi ZF, Li KK et al (2022) Combinations of single-gene biomarkers can precisely stratify 1028 adult gliomas for prognostication. Front Oncol 12:839302. https://doi.org/10.3389/fonc.2022.839302
doi: 10.3389/fonc.2022.839302
pubmed: 35558510
pmcid: 9090434
Di Stefano AL, Enciso-Mora V, Marie Y et al (2013) Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies. Neuro Oncol 15:542–547
pubmed: 23161787
doi: 10.1093/neuonc/nos284
Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508
pubmed: 26061753
pmcid: 4489704
doi: 10.1056/NEJMoa1407279
Fleming JL, Pugh SL, Fisher BJ et al (2021) Long-term report of a comprehensive molecular and genomic analysis in NRG oncology/RTOG 0424: a phase II study of radiation and temozolomide in high-risk grade II glioma. JCO Precis Oncol. https://doi.org/10.1200/po.21.00112
doi: 10.1200/po.21.00112
pubmed: 34589661
pmcid: 8457832
Fujimoto K, Arita H, Satomi K et al (2021) TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta Neuropathol 142:323–338
pubmed: 34148105
doi: 10.1007/s00401-021-02337-9
Gorovets D, Kannan K, Shen R et al (2012) IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res 18:2490–2501
pubmed: 22415316
doi: 10.1158/1078-0432.CCR-11-2977
Grogan D, Bray DP, Cosgrove M et al (2022) Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review. J Neurooncol 157:187–195
pubmed: 35212929
pmcid: 9703358
doi: 10.1007/s11060-022-03961-5
Hasanau T, Pisarev E, Kisil O et al (2022) Detection of TERT promoter mutations as a prognostic biomarker in gliomas: methodology, prospects, and advances. Biomedicines. https://doi.org/10.3390/biomedicines10030728
doi: 10.3390/biomedicines10030728
pubmed: 35327529
pmcid: 8945783
Hattori N, Hirose Y, Sasaki H et al (2016) World health organization grade II-III astrocytomas consist of genetically distinct tumor lineages. Cancer Sci 107:1159–1164
pubmed: 27196377
pmcid: 4982592
doi: 10.1111/cas.12969
Heidenreich B, Rachakonda PS, Hosen I et al (2015) TERT promoter mutations and telomere length in adult malignant gliomas and recurrences. Oncotarget 6:10617–10633
pubmed: 25797251
pmcid: 4496380
doi: 10.18632/oncotarget.3329
Higa N, Akahane T, Yokoyama S et al (2022) Molecular genetic profile of 300 Japanese patients with diffuse gliomas using a glioma-tailored gene panel. Neurol Med Chir (Tokyo) 62:391–399. https://doi.org/10.2176/jns-nmc.2022-0103
doi: 10.2176/jns-nmc.2022-0103
pubmed: 36031351
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13
doi: 10.1186/1471-2288-5-13
pubmed: 15840177
pmcid: 1097734
Ichimura K (2019) TERT promoter mutation as a diagnostic marker for diffuse gliomas. Neuro Oncol 21:417–418
pubmed: 30852620
pmcid: 6422426
doi: 10.1093/neuonc/noz025
Izquierdo C, Barritault M, Poncet D et al (2019) Radiological characteristics and natural history of adult IDH-wildtype astrocytomas with TERT promoter mutations. Neurosurgery 85:E448–E456. https://doi.org/10.1093/neuros/nyy513
doi: 10.1093/neuros/nyy513
pubmed: 30407589
Jiang C, Kong Z, Zhang Y et al (2020) Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas. Neuroradiology 62:803–813
pubmed: 32239241
doi: 10.1007/s00234-020-02392-1
Killela PJ, Pirozzi PC, Healy P et al (2014) Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget 5:1515–1525
pubmed: 24722048
pmcid: 4039228
doi: 10.18632/oncotarget.1765
Komori T (2023) Update of the 2021 WHO classification of tumors of the central nervous system: adult diffuse gliomas. Brain Tumor Pathol 40:1–3. https://doi.org/10.1007/s10014-022-00446-1
doi: 10.1007/s10014-022-00446-1
pubmed: 36538117
Kumari K, Dandapath I, Singh J et al (2022) Molecular characterization of IDH wild-type diffuse astrocytomas: the potential of cIMPACT-NOW guidelines. App Immunohistochem Mol Morphol 30:410–417
doi: 10.1097/PAI.0000000000001038
Kuwahara K, Ohba S, Nakae S et al (2019) Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis. Brain Tumor Pathol 36:135–143
pubmed: 31324999
doi: 10.1007/s10014-019-00348-9
Lasica AB, Jaunmuktane Z, Fersht N et al (2021) Genomic prognosticators and extent of resection in molecularly subtyped World Health Organization grade II and III gliomas-A single-institution, nine-year data. World Neurosurg 151:e217–e233
pubmed: 33866029
doi: 10.1016/j.wneu.2021.04.026
Li J, Xue Y, Wenger A et al (2019) Individual assignment of adult diffuse gliomas into the EM/PM molecular subtypes using a TaqMan low-density array. Clin Cancer Res 25:7068–7077
pubmed: 31481507
doi: 10.1158/1078-0432.CCR-19-0299
Lin AL, Rosenblum M, Mellinghoff IK et al (2020) Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. Brain Pathol 30:653–660
pubmed: 31984581
pmcid: 7647462
doi: 10.1111/bpa.12826
Ma S, Rudra S, Campian JL et al (2020) Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neurooncol Adv 2:vdaa26. https://doi.org/10.1093/noajnl/vdaa126
doi: 10.1093/noajnl/vdaa126
Makino Y, Arakawa Y, Yoshioka E et al (2021) Prognostic stratification for IDH-wild-type lower-grade astrocytoma by sanger sequencing and copy-number alteration analysis with MLPA. Sci Rep 11:14408
pubmed: 34257410
pmcid: 8277860
doi: 10.1038/s41598-021-93937-8
Mesny E, Barritault M, Izquierdo C et al (2022) Gyriform infiltration as imaging biomarker for molecular glioblastomas. J Neurooncol 157:511–521
pubmed: 35364762
doi: 10.1007/s11060-022-03995-9
Mizoguchi M, Hata N, Kuga D et al (2021) Clinical implications of molecular analysis in diffuse glioma stratification. Brain Tumor Pathol 38:210–217
pubmed: 34268651
doi: 10.1007/s10014-021-00409-y
Mo Z, Xin J, Chai R et al (2022) Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations. Cancer Biol Med 19:1440–1459
pubmed: 36350002
pmcid: 9630523
doi: 10.20892/j.issn.2095-3941.2022.0418
Mortensen D, Ulhoi BP, Lukacova S et al (2022) Impact of new molecular criteria on diagnosis and survival of adult glioma patients. IBRO Neurosci Rep 13:299–305
pubmed: 36204252
pmcid: 9529576
doi: 10.1016/j.ibneur.2022.09.005
Nakasu S, Nakasu Y (2022) Malignant progression of diffuse low-grade gliomas: a systematic review and meta-analysis on incidence and related factors. Neurol Med Chir (Tokyo) 62:177–185
pubmed: 35197400
doi: 10.2176/jns-nmc.2021-0313
Nakasu S, Nakasu Y, Tsuji A et al (2023) Incidental diffuse low-grade gliomas: a systematic review and meta-analysis of treatment results with correction of lead-time and length-time biases. Neuro-Oncol Pract 10:113–125. https://doi.org/10.1093/nop/npac073
doi: 10.1093/nop/npac073
Park YW, Kim S, Park CJ et al (2022) Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status. Eur Radiol 32:8089–8098. https://doi.org/10.1007/s00330-022-08941-x
doi: 10.1007/s00330-022-08941-x
pubmed: 35763095
Pekmezci M, Rice T, Molinaro AM et al (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001–1016
pubmed: 28255664
pmcid: 5432658
doi: 10.1007/s00401-017-1690-1
Petersen JK, Boldt HB, Sorensen MD et al (2021) Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics. Neuropathol Appl Neurobiol 47:108–126
pubmed: 32696543
doi: 10.1111/nan.12645
Poulen G, Gozé C, Rigau V, Duffau H (2018) Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas. J Neurosurg 130:1289–1298
doi: 10.3171/2017.10.JNS171825
Ramos-Fresnedo A, Domingo RA, Perez-Vega C et al (2022) The early infiltrative phase of GBM hypothesis: are molecular glioblastomas histological glioblastomas in the making? A preliminary multicenter study. J Neurooncol 158:497–506
pubmed: 35699848
doi: 10.1007/s11060-022-04040-5
Ramos-Fresnedo A, Pullen MW, Perez-Vega C et al (2022) The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study. J Neurooncol 157:177–185
pubmed: 35175545
doi: 10.1007/s11060-022-03960-6
Reuss DE, Kratz A, Sahm F et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417
pubmed: 26087904
doi: 10.1007/s00401-015-1454-8
Ruda R, Bruno F, Ius T et al (2022) IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. Neuro Oncol 24:809–820
pubmed: 34651653
doi: 10.1093/neuonc/noab239
Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561
pubmed: 21971842
doi: 10.1007/s10147-011-0323-2
Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803
pubmed: 30187121
doi: 10.1007/s00401-018-1905-0
Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468
pubmed: 25848751
doi: 10.1038/ng.3273
Tabouret E, Nguyen AT, Dehais C et al (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132:625–634
pubmed: 27573687
doi: 10.1007/s00401-016-1611-8
Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol 22:515–523
pubmed: 31637414
doi: 10.1093/neuonc/noz200
Teske N, Karschnia P, Weller J et al (2022) Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma? J Neurooncol 156:317–327
pubmed: 34902093
doi: 10.1007/s11060-021-03912-6
Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https://doi.org/10.1186/1745-6215-8-16
doi: 10.1186/1745-6215-8-16
pubmed: 17555582
pmcid: 1920534
Wang P, Luo C, Hong PJ et al (2021) The role of surgery in IDH-wild-type lower-grade gliomas: threshold at a high extent of resection should be pursued. Neurosurgery 88:1136–1144
pubmed: 33647953
doi: 10.1093/neuros/nyab052
Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693
pubmed: 25783747
doi: 10.1007/s00401-015-1409-0
Wijnenga MMJ, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959
pubmed: 29052002
doi: 10.1007/s00401-017-1781-z
Yang P, Cai J, Yan W et al (2016) Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Neuro Oncol 18:1099–1108
pubmed: 26957363
pmcid: 4933482
doi: 10.1093/neuonc/now021
Yang Z, Ling F, Ruan S et al (2021) Clinical and Prognostic Implications of 1p/19q, IDH, BRAF, MGMT Promoter, and TERT Promoter Alterations, and Expression of Ki-67 and p53 in Human Gliomas. Cancer Manag Res 13:8755–8765
pubmed: 34849029
pmcid: 8627377
doi: 10.2147/CMAR.S336213
Zhang Y, Lucas CG, Young JS et al (2022) Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol 24:1749–1762
pubmed: 35395677
pmcid: 9527525
doi: 10.1093/neuonc/noac089
Zhang ZY, Zhan YB, Zhang FJ et al (2019) Prognostic value of preoperative hematological markers combined with molecular pathology in patients with diffuse gliomas. Aging (Albany NY) 11:6252–6272
pubmed: 31444316
doi: 10.18632/aging.102186